You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯邦制藥(03933.HK):6個胰島素產品擬中標胰島素專項國採
格隆匯 11-29 23:23

格隆匯11月29日丨聯邦制藥(03933.HK)公吿,公司全資附屬公司珠海聯邦制藥股份有限公司及珠海聯邦制藥股份有限公司中山分公司於2021年11月26日參加了國家組織藥品聯合採購辦公室組織的第六批國家藥品集中採購(胰島素專項)的投標工作。公司胰島素產品擬中標本次集中採購。藥品名稱分別為:人胰島素注射液、精蛋白人胰島素注射液、精蛋白人胰島素混合注射液(30R/50R)、門冬胰島素注射液、甘精胰島素注射液、門冬胰島素30注射液。

本次集中採購是國家組織的第六批藥品集中帶量採購(胰島素專項),採購產品涉及餐時、基礎、預混組別的人胰島素及胰島素類似物。本次採購週期為兩年,醫藥機構將優先使用本次集中採購中選藥品,並確保完成協議採購量。

本次公司擬中選產品價格與原價格相比有一定幅度下降,但有約定的採購基礎量的保障。同時公司A類和B類中標產品還將獲得C類和D類產品調出的分配量。若公司確定中標及後續簽訂並執行採購協議,將有助於拓展相關產品的銷售,提高胰島素產品市場佔有率,提升公司品牌影響力,惠及廣大糖尿病患者,加速國產替代,對公司未來的經營發展具有積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account